发布求助
文献互助 智能选刊 最新文献

Precision cancer medicine最新文献

筛选
英文 中文
Role of Pathologist in Precision Cancer Diagnosis 病理学家在癌症精确诊断中的作用
Precision cancer medicine Pub Date : 2021-01-01 DOI: 10.1007/978-3-030-84087-7_16
B. Jasani, R. Huss, C. Taylor
{"title":"Role of Pathologist in Precision Cancer Diagnosis","authors":"B. Jasani, R. Huss, C. Taylor","doi":"10.1007/978-3-030-84087-7_16","DOIUrl":"https://doi.org/10.1007/978-3-030-84087-7_16","url":null,"abstract":"","PeriodicalId":74487,"journal":{"name":"Precision cancer medicine","volume":"61 3","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"50981414","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
AI in the Analytical Phase 分析阶段的人工智能
Precision cancer medicine Pub Date : 2021-01-01 DOI: 10.1007/978-3-030-84087-7_20
Bharat Jasani, R. Huss, C. Taylor
{"title":"AI in the Analytical Phase","authors":"Bharat Jasani, R. Huss, C. Taylor","doi":"10.1007/978-3-030-84087-7_20","DOIUrl":"https://doi.org/10.1007/978-3-030-84087-7_20","url":null,"abstract":"","PeriodicalId":74487,"journal":{"name":"Precision cancer medicine","volume":"26 4","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"50981600","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
AI in the Post-Analytical Phase 后分析阶段的人工智能
Precision cancer medicine Pub Date : 2021-01-01 DOI: 10.1007/978-3-030-84087-7_21
Bharat Jasani, R. Huss, C. Taylor
{"title":"AI in the Post-Analytical Phase","authors":"Bharat Jasani, R. Huss, C. Taylor","doi":"10.1007/978-3-030-84087-7_21","DOIUrl":"https://doi.org/10.1007/978-3-030-84087-7_21","url":null,"abstract":"","PeriodicalId":74487,"journal":{"name":"Precision cancer medicine","volume":"139 3","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"50981639","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Moving through rare lung cancer histologies: a narrative review on diagnosis and treatment of selected infrequent entities 通过罕见的癌症组织学：选择罕见实体的诊断和治疗的叙述性综述
Precision cancer medicine Pub Date : 2021-01-01 DOI: 10.21037/pcm-22-4
C. Pisano, G. Witel, M. De Filippis, A. Listì, F. Napoli, L. Righi, S. Novello, P. Bironzo
{"title":"Moving through rare lung cancer histologies: a narrative review on diagnosis and treatment of selected infrequent entities","authors":"C. Pisano, G. Witel, M. De Filippis, A. Listì, F. Napoli, L. Righi, S. Novello, P. Bironzo","doi":"10.21037/pcm-22-4","DOIUrl":"https://doi.org/10.21037/pcm-22-4","url":null,"abstract":"","PeriodicalId":74487,"journal":{"name":"Precision cancer medicine","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44934589","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Uncommon EGFR mutations: state-of-the-art and case reports 罕见的EGFR突变：最新进展和病例报告
Precision cancer medicine Pub Date : 2021-01-01 DOI: 10.21037/pcm-21-20
Francesca Simionato, L. Calvetti
{"title":"Uncommon EGFR mutations: state-of-the-art and case reports","authors":"Francesca Simionato, L. Calvetti","doi":"10.21037/pcm-21-20","DOIUrl":"https://doi.org/10.21037/pcm-21-20","url":null,"abstract":"","PeriodicalId":74487,"journal":{"name":"Precision cancer medicine","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45124366","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Mechanisms of resistance after crizotinib or second-generation ALK therapy in advanced non-small cell lung cancer 克唑替尼或第二代ALK治疗晚期癌症后的耐药性机制
Precision cancer medicine Pub Date : 2021-01-01 DOI: 10.21037/pcm-20-33
J. Remon, Laura Esteller, L. Hendriks
{"title":"Mechanisms of resistance after crizotinib or second-generation ALK therapy in advanced non-small cell lung cancer","authors":"J. Remon, Laura Esteller, L. Hendriks","doi":"10.21037/pcm-20-33","DOIUrl":"https://doi.org/10.21037/pcm-20-33","url":null,"abstract":"","PeriodicalId":74487,"journal":{"name":"Precision cancer medicine","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46837546","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
From icing to slicing the cake: the new hope of precision medicine for lung cancer 从糖衣到切块：精准医疗治疗癌症的新希望
Precision cancer medicine Pub Date : 2021-01-01 DOI: 10.21037/pcm-21-39
G. Banna, A. Addeo
{"title":"From icing to slicing the cake: the new hope of precision medicine for lung cancer","authors":"G. Banna, A. Addeo","doi":"10.21037/pcm-21-39","DOIUrl":"https://doi.org/10.21037/pcm-21-39","url":null,"abstract":"","PeriodicalId":74487,"journal":{"name":"Precision cancer medicine","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48526191","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Sex-based heterogeneity in non-small cell lung cancer (NSCLC) and response to immune checkpoint inhibitors (ICIs): a narrative review 非小细胞肺癌(NSCLC)的性别异质性和对免疫检查点抑制剂(ICIs)的反应:一项叙述性综述
Precision cancer medicine Pub Date : 2021-01-01 DOI: 10.21037/pcm-21-7
S. Frega, A. Ferro, L. Bonanno, V. Guarneri, P. Conte, G. Pasello
{"title":"Sex-based heterogeneity in non-small cell lung cancer (NSCLC) and response to immune checkpoint inhibitors (ICIs): a narrative review","authors":"S. Frega, A. Ferro, L. Bonanno, V. Guarneri, P. Conte, G. Pasello","doi":"10.21037/pcm-21-7","DOIUrl":"https://doi.org/10.21037/pcm-21-7","url":null,"abstract":"Objective: The aim of our review is to analyse sex-based differences in advanced non-small cell lung cancer (aNSCLC) patients in terms of clinical-pathological and molecular features, focusing on their impact on immune response and outcome. Background: Lung cancer (LC) remains the leading cause of cancer mortality both in men and women worldwide. In the era of precision oncology, the idea of unleashing the host immune system against cancer through the development of immune checkpoint inhibitors (ICIs) radically shaped the therapeutic approach in the setting of non-oncogene addicted aNSCLC. Despite durable remissions and prolonged survival in a subset of patients, potential markers for individual prediction of immunotherapy effectiveness lacked high sensitivity and specificity. The selection of patients who could most benefit from single ICIs remains an unmet need, as well as the improvement of combination strategies for those one unresponsive or refractory to immunotherapy. Sex is a known variable that affects both innate and adaptive immune responses, as well as possibly clinical-pathological and molecular basis of LC. Although smoking is the primary risk factor for LC development in both men and women, other variable such as genetic differences, sex hormones, environmental exposures and lifestyle habit, immune system and tumor microenvironment (TME) disparities, could play an important role in sex-biased carcinogenesis and development of immune responses. Methods: An extended review of literature through PubMed was conducted, using the keywords related to patient sex (“sex”, “gender”, “male/female”, “men/women”) and NSCLC and LC epidemiological, etiological, clinical-pathological and molecular features. Conclusions: Women vs . men differences in terms of response to ICIs remain to date only suggestive, so further research, including prospective clinical trials, is warranted to establish sex as a factor in the therapeutic decision-making process. These findings about male vs. female immune","PeriodicalId":74487,"journal":{"name":"Precision cancer medicine","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48646897","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Metabolic reprogramming and cancer precision medicine: a narrative review 代谢重编程与癌症精准医学:叙述性回顾
Precision cancer medicine Pub Date : 2021-01-01 DOI: 10.21037/pcm-21-27
Hong Zhang, Shuang Tang
{"title":"Metabolic reprogramming and cancer precision medicine: a narrative review","authors":"Hong Zhang, Shuang Tang","doi":"10.21037/pcm-21-27","DOIUrl":"https://doi.org/10.21037/pcm-21-27","url":null,"abstract":"Precision medicine in cancer aims to improve outcome of cancer patients by using customized strategy to prevent, diagnose and treat cancer according to tumor molecular features. As the metabolic reprogramming empowers cancer cells flexibility to adapt stress and microenvironment, metabolic reprogramming is critical for tumorigenesis, cancer progression, tumor responses upon treatment, and therapy resistance. Therefore, targeting cancer metabolism can provide effective approaches for cancer precision management. Increasing research in cancer metabolism investigate how reprogrammed metabolism works and drives rapid cell proliferation, or which reprogrammed activities are relevant to resistance of treatment. Deep understanding of these molecular insights about cancer metabolism is the foundation for design of effective cancer management and therapeutic strategies for different cancer Review Article","PeriodicalId":74487,"journal":{"name":"Precision cancer medicine","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49108666","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
Outcomes of head and neck angiosarcoma with different treatment modalities: a 20-year single institutional experience 不同治疗方式治疗头颈部血管肉瘤的疗效：20年的单一机构经验
Precision cancer medicine Pub Date : 2021-01-01 DOI: 10.21037/pcm-21-40
Y. S. Koh, J. Chan, W. S. Looi, M. Farid, N. Iyer, C. Tay, K. Sommat, R. Wong
{"title":"Outcomes of head and neck angiosarcoma with different treatment modalities: a 20-year single institutional experience","authors":"Y. S. Koh, J. Chan, W. S. Looi, M. Farid, N. Iyer, C. Tay, K. Sommat, R. Wong","doi":"10.21037/pcm-21-40","DOIUrl":"https://doi.org/10.21037/pcm-21-40","url":null,"abstract":"","PeriodicalId":74487,"journal":{"name":"Precision cancer medicine","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47837970","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：604180095
Book学术官方微信